Pharma Industry Urges HTA Bodies To Look Beyond Survival Data For Cancer Drugs
Executive Summary
A new report by industry association EFPIA says that health technology assessment bodies often rely too heavily on overall survival data when assessing the value of novel cancer drugs, and should take into account other clinical and patient-reported outcome measures where appropriate.